International journal of clinical practice
-
Int. J. Clin. Pract. · Nov 2021
Randomized Controlled TrialComparison of intraoral mask and classic face mask in terms of ventilation success and practitioners' workload assessments: A randomised crossover study.
Providing effective ventilation of the unconscious patient is an essential skill in every specialty dealing with airway management. In this randomised crossover study aimed to compare intraoral and classic face mask in terms of ventilation success of patients, practitioners' workload and anxiety assessments. Also we analysed potential risk factors of difficult mask ventilation for both masks. ⋯ Intraoral mask may be an effective alternative device for bag-valve mask ventilation.
-
Int. J. Clin. Pract. · Nov 2021
Randomized Controlled TrialOmega 3-rich Camelina Sativa in the context of a weight loss programs improves glucose homeostasis, inflammation and oxidative stress in NAFLD patients: A randomized placebo-controlled clinical trial.
Over the past few years, the benefits of omega-3 fatty acids have been reported in the management of non-alcoholic fatty liver disease (NAFLD) complications.This study evaluated the effects of Camelina sativa oil (CSO) supplementation as one of the richest dietary sources of omega-3 fatty acids on glucose homeostasis,inflammation, metabolic endotoxemia, and oxidative stress in NAFLD patients. ⋯ These findings indicate that CSO may improve glycemia, inflammation, metabolic endotoxemia, and oxidative stress status in patients with NAFLD.
-
Int. J. Clin. Pract. · Nov 2021
Randomized Controlled TrialDoes Naringenin Supplementation Improve Lipid Profile, Severity of Hepatic Steatosis, and Probability of Liver Fibrosis in Overweight/Obese Patients with NAFLD? A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.
Naringenin has been reported to have some promising pharmacological effects on the management of obesity and related metabolic complications including non-alcoholic fatty liver disease (NAFLD). Therefore, the present clinical trial study was done to assess the effects of naringenin supplementation on lipid profile, aminotransferase levels, severity of steatosis, as well as probability of fibrosis in overweight/obese patients with NAFLD. ⋯ Our findings revealed that daily intake of 200 mg of naringenin for 4 weeks had beneficial effects on lipid profile and percentages of NAFLD grades as an indicator for the severity of hepatic steatosis. Although, NFS values and serum levels of aminotransferase enzymes including AST and ALT did not remarkably change.
-
Int. J. Clin. Pract. · Nov 2021
Randomized Controlled TrialEvaluation of Ultrasound-Guided Adductor Canal Block With Two Different Concentration of Bupivacaine in Arthroscopic Knee Surgery, A Feasibility Study.
The application of regional anaesthesia techniques as a component of multimodal analgesia in knee arthroscopic surgeries increases the quality of postoperative analgesia. Adductor canal block (ACB) is an effective "motor sparing" analgesia technique used in knee surgeries. This study aimed to evaluate the efficacy of ACB using two different concentrations of local anaesthetic in terms of analgesic requirements and pain density in patients undergoing knee arthroscopy. ⋯ In arthroscopic knee surgery, ACB interventions with 0.25% and 0.16% concentrations of bupivacaine were similar in terms of postoperative analgesic efficacy, and they increased the quality of multimodal analgesics when compared with the control group.
-
Int. J. Clin. Pract. · Nov 2021
Randomized Controlled TrialRifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with HCV related cirrhosis.
Rifaximin is an oral antibiotic with promising efficacy in the reduction of hepatic encephalopathy (HE) recurrence. Development of microbial resistance to rifaximin is not studied yet in HE. The study aim was to assess the microbial resistance, safety and efficacy of rifaximin as secondary prophylaxis of HE. ⋯ Rifaximin succeeded to maintain remission from new episodes of HE in hepatitis C virus cirrhotic patients with limited potential for development of microbial resistance over the study period. ClinicalTrials.gov Identifier: NCT04736836.